PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL)

An abstract of a study by Arribas et al on PQR309, idelalisib, duvelisib and ibrutinib that lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL) is presented. Gene expression profiling was obtained with the lllumina-HumanHT-12 Expression-BeadChips and analyzed with limma t-test. A GSEA was performed using the limma-derived gene expression profiling signatures obtained for each drug. The study demonstrated the targeted fundamental pathways of all models sustaining lymphoma cell proliferation and survival. Their early effects on the lymphoma cell transcriptome were very similar, but with varied degree of changes among drugs, possibly reflecting their main targets.